{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:08:42Z","timestamp":1794074922796,"version":"4.8.0"},"reference-count":208,"publisher":"Japan Endocrine Society","issue":"1","funder":[{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["27-1402"],"award-info":[{"award-number":["27-1402"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["30-1008"],"award-info":[{"award-number":["30-1008"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["24A1004"],"award-info":[{"award-number":["24A1004"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1041"],"award-info":[{"award-number":["23FC1041"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109112"],"award-info":[{"award-number":["JP17ek0109112"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ek0109352"],"award-info":[{"award-number":["JP20ek0109352"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0165","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:08:28Z","timestamp":1760047708000},"page":"115-157","source":"Crossref","is-referenced-by-count":24,"title":["Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5682-4952","authenticated-orcid":false,"given":"Akiyo","family":"Tanabe","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Hospital; Director, Endocrinology and Adrenal Tumor Center, Tokyo 162-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-8645","authenticated-orcid":false,"given":"Takuyuki","family":"Katabami","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University Yokohama Seibu Hospital, Yokohama 226-0015, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeatsu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Diabetology and Nephrology, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu 969-3492, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-2875","authenticated-orcid":false,"given":"Shoichiro","family":"Izawa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago 683-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2969-7396","authenticated-orcid":false,"given":"Takamasa","family":"Ichijo","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Tobu Hospital, Yokohama 230-8765, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-8621","authenticated-orcid":false,"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-0620","authenticated-orcid":false,"given":"Noboru","family":"Oriuchi","sequence":"additional","affiliation":[{"name":"Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Kanazawa University, Kanazawa 920-8640, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6481-1967","authenticated-orcid":false,"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University, Hirakata 573-1010, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-3687","authenticated-orcid":false,"given":"Noriko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Hospital Organization Hakodate Medical Center, Hakodate 041-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6506-4820","authenticated-orcid":false,"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology, and Nephrology, Faculty of Medicine, Oita University, Yufu 879-5593, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-7529","authenticated-orcid":false,"given":"Masakatsu","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Showa General Hospital, Kodaira 187-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-7546","authenticated-orcid":false,"given":"Nae","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University, Hirakata 573-1010, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takekoshi","sequence":"additional","affiliation":[{"name":"Laboratory of Laboratory\/Sports Medicine, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tsuiki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6823-9938","authenticated-orcid":false,"given":"Kanako","family":"Tanase-Nakao","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6709-2876","authenticated-orcid":false,"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Pathology, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, International Medical Center, Saitama Medical University, Hidaka 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0143-3989","authenticated-orcid":false,"given":"Tomonobu","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-3502","authenticated-orcid":false,"given":"Masanori","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3389-9832","authenticated-orcid":false,"given":"Masato","family":"Yonamine","sequence":"additional","affiliation":[{"name":"Laboratory of Laboratory\/Sports Medicine, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-4090","authenticated-orcid":false,"given":"Mitsuhide","family":"Naruse","sequence":"additional","affiliation":[{"name":"Endocrine Center and Clinical Research Center, Ijinkai Takeda General Hospital, Kyoto 601-1495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"2 Takeda R, Yasuhara S, Miyamori I, Sato T, Miura Y (1986) Phaeochromocytoma in Japan: analysis of 493 cases during 1973\u20131982. J Hypertens 4 (Suppl 5): S397\u2013S399."},{"key":"2","doi-asserted-by":"crossref","unstructured":"3 Takayanagi R, Miura K, Nakagawa H, Nawata H (2000) Epidemiologic study of adrenal gland disorders in Japan. Biomed Pharmacother 54 Suppl 1: 164s\u2013168s.","DOI":"10.1016\/S0753-3322(00)80036-0"},{"key":"3","unstructured":"4 Naruse M, Taskforce of the research project for overcoming intractable diseases, Ministry of Health, Labour and Welfare of Japan (2010) Fiscal year 2010 report on the research of the advancement of diagnosis and treatment of pheochromocytoma (In Japanese)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"5 Tanabe A, Naruse M (2020) Recent advances in the management of pheochromocytoma and paraganglioma. Hypertens Res 43: 1141\u20131151.","DOI":"10.1038\/s41440-020-0531-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6 Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, et al. (2021) Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study. J Clin Endocrinol Metab 106: e2251\u2013e2261.","DOI":"10.1210\/clinem\/dgaa965"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7 Leung AA, Pasieka JL, Hyrcza MD, Pacaud D, Dong Y, et al. (2021) Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study. Eur J Endocrinol 184: 19\u201328.","DOI":"10.1530\/EJE-20-0628"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8 Berends AMA, Buitenwerf E, de Krijger RR, Veeger N, van der Horst-Schrivers ANA, et al. (2018) Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med 51: 68\u201373.","DOI":"10.1016\/j.ejim.2018.01.015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9 Pommer G, Pamporaki C, Peitzsch M, Remde H, Deutschbein T, et al. (2022) Preanalytical considerations and outpatient <i>versus<\/i> inpatient tests of plasma metanephrines to diagnose pheochromocytoma. J Clin Endocrinol Metab 107: e3689\u2013e3698.","DOI":"10.1210\/clinem\/dgac390"},{"key":"9","doi-asserted-by":"publisher","unstructured":"10 Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366: 665\u2013675.","DOI":"10.1016\/S0140-6736(05)67139-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Barrett C, van Uum SH, Lenders JW (2015) Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review. Clin Endocrinol (Oxf) 83: 622\u2013628.","DOI":"10.1111\/cen.12813"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12 Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, et al. (2016) European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174: G1\u2013g10.","DOI":"10.1530\/EJE-16-0033"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13 Kudva YC, Sawka AM, Young WF, Jr. (2003) Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 88: 4533\u20134539.","DOI":"10.1210\/jc.2003-030720"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14 Bravo EL (2004) Pheochromocytoma: current perspectives in the pathogenesis, diagnosis, and management. Arq Bras Endocrinol Metabol 48: 746\u2013750.","DOI":"10.1590\/S0004-27302004000500021"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15 Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, et al. (2002) Biochemical diagnosis of pheochromocytoma: which test is best? Jama 287: 1427\u20131434.","DOI":"10.1001\/jama.287.11.1427"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16 Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr. (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88: 553\u2013558.","DOI":"10.1210\/jc.2002-021251"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17 Grouzmann E, Drouard-Troalen L, Baudin E, Plouin PF, Muller B, et al. (2010) Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol 162: 951\u2013960.","DOI":"10.1530\/EJE-09-0996"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18 Takekoshi K, Satoh F, Tanabe A, Okamoto T, Ichihara A, et al. (2019) Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: a subanalysis of a multicenter, open-label phase I\/II study. Endocr J 66: 1063\u20131072.","DOI":"10.1507\/endocrj.EJ19-0125"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19 Peitzsch M, Kaden D, Pamporaki C, Langton K, Constantinescu G, et al. (2020) Overnight\/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option? Eur J Endocrinol 182: 499\u2013509.","DOI":"10.1530\/EJE-19-1016"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Sbardella E, Maunsell Z, May CJH, Tadman M, James T, et al. (2020) Random \u2018spot\u2019 urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas. Eur J Endocrinol 183: 129\u2013139.","DOI":"10.1530\/EJE-19-0809"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21 Kline GA, Boyd J, Sadrzadeh HSM, Leung AA (2021) Inpatient measurements of urine metanephrines are indistinguishable from pheochromocytoma: retrospective cohort study. Am J Med 134: 1039\u20131046.e1033.","DOI":"10.1016\/j.amjmed.2021.03.015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22 Ohno Y, Sone M, Taura D, Yamasaki T, Kojima K, et al. (2018) Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors. Hypertens Res 41: 165\u2013175.","DOI":"10.1038\/s41440-017-0002-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23 Kawashima A, Sone M, Inagaki N, Okamoto K, Tsuiki M, et al. (2021) Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases. Endocrine 74: 155\u2013162.","DOI":"10.1007\/s12020-021-02816-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24 Casey R, Griffin TP, Wall D, Dennedy MC, Bell M, et al. (2017) Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted\/seated patients. Ann Clin Biochem 54: 170\u2013173.","DOI":"10.1177\/0004563216646395"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Chen Y, Xiao H, Zhou X, Huang X, Li Y, et al. (2017) Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 23: 1169\u20131177.","DOI":"10.4158\/EP171877.OR"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Tanaka Y, Isobe K, Ma E, Imai T, Kikumori T, et al. (2014) Plasma free metanephrines in the diagnosis of pheochromocytoma: diagnostic accuracy and strategies for Japanese patients. Endocr J 61: 667\u2013673.","DOI":"10.1507\/endocrj.EJ13-0277"},{"key":"26","doi-asserted-by":"publisher","unstructured":"27 D\u00e4rr R, Kuhn M, Bode C, Bornstein SR, Pacak K, et al. (2017) Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine 56: 495\u2013503.","DOI":"10.1007\/s12020-017-1300-y"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28 Wang K, Gao X, Zhang W, Sun N, Xie L, et al. (2021) Study of stability and interference for catecholamines and metanephrines, 3-methoxytyramine: key point of an accurate diagnosis for pheochromocytoma and paraganglioma. Scand J Clin Lab Invest 81: 564\u2013572.","DOI":"10.1080\/00365513.2021.1980901"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29 B\u00edlek R, Vl\u010dek P, \u0160afa\u0159\u00edk L, Michalsk\u00fd D, Nov\u00e1k K, et al. (2019) Chromogranin A in the laboratory diagnosis of pheochromocytoma and paraganglioma. <i>Cancers (Basel)<\/i> 11.","DOI":"10.3390\/cancers11040586"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30 Liu L, Xie W, Song Z, Wang T, Li X, et al. (2022) Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy. Clin Endocrinol (Oxf) 96: 132\u2013138.","DOI":"10.1111\/cen.14585"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31 Lamy C, Tissot H, Faron M, Baudin E, Lamartina L, et al. (2022) Succinate: a serum biomarker of SDHB-mutated paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 107: 2801\u20132810.","DOI":"10.1210\/clinem\/dgac474"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32 Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, et al. (2003) Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 88: 2656\u20132666.","DOI":"10.1210\/jc.2002-030005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33 Tsiomidou S, Pamporaki C, Geroula A, Van Baal L, Weber F, et al. (2022) Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use. Clin Endocrinol (Oxf) 97: 541\u2013550.","DOI":"10.1111\/cen.14724"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34 Lenders JW, Pacak K, Huynh TT, Sharabi Y, Mannelli M, et al. (2010) Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 95: 238\u2013245.","DOI":"10.1210\/jc.2009-1850"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35 Lumachi F, Tregnaghi A, Zucchetta P, Cristina Marzola M, Cecchin D, et al. (2006) Sensitivity and positive predictive value of CT, MRI and <sup>123<\/sup>I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 27: 583\u2013587.","DOI":"10.1097\/00006231-200607000-00006"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36 Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, et al. (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by <sup>18<\/sup>F-fluorodeoxyglucose (<sup>18<\/sup>F-FDG) positron emission tomography. J Natl Cancer Inst 104: 700\u2013708.","DOI":"10.1093\/jnci\/djs188"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37 Corral de la Calle MA, Encinas de la Iglesia J, Fern\u00e1ndez-P\u00e9rez GC, Repoll\u00e9s Cobaleda M, Fraino A (2022) Adrenal pheochromocytoma: Keys to radiologic diagnosis. Radiologia (Engl Ed) 64: 348\u2013367.","DOI":"10.1016\/j.rxeng.2022.07.002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38 Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, et al. (2013) Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 98: E162\u2013E173.","DOI":"10.1210\/jc.2012-2975"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39 De Leo A, Vara G, Paccapelo A, Balacchi C, Vicennati V, et al. (2022) Computerized tomography texture analysis of pheochromocytoma: relationship with hormonal and histopathological data. J Endocrinol Invest 45: 1935\u20131944.","DOI":"10.1007\/s40618-022-01826-2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, et al. (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 1915\u20131942.","DOI":"10.1210\/jc.2014-1498"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41 Gerson R, Tu W, Abreu-Gomez J, Udare A, McPhedran R, et al. (2022) Evaluation of the T2-weighted (T2W) adrenal MRI calculator to differentiate adrenal pheochromocytoma from lipid-poor adrenal adenoma. Eur Radiol 32: 8247\u20138255.","DOI":"10.1007\/s00330-022-08867-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42 Takano A, Oriuchi N, Tsushima Y, Taketomi-Takahashi A, Nakajima T, et al. (2008) Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with <sup>18<\/sup>F-FDG positron emission tomography and <sup>123<\/sup>I-MIBG scintigraphy. Ann Nucl Med 22: 395\u2013401.","DOI":"10.1007\/s12149-008-0128-1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43 Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR (2010) <sup>123<\/sup>I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 95: 2596\u20132606.","DOI":"10.1210\/jc.2009-2604"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44 King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, et al. (2011) Functional imaging of SDHx-related head and neck paragangliomas: comparison of <sup>18<\/sup>F-fluorodihydroxyphenylalanine, <sup>18<\/sup>F-fluorodopamine, <sup>18<\/sup>F-fluoro-2-deoxy-D-glucose PET, <sup>123<\/sup>I-metaiodobenzylguanidine scintigraphy, and <sup>111<\/sup>In-pentetreotide scintigraphy. J Clin Endocrinol Metab 96: 2779\u20132785.","DOI":"10.1210\/jc.2011-0333"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45 Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, et al. (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25: 2262\u20132269.","DOI":"10.1200\/JCO.2006.09.6297"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46 Cypess AM, Lehman S, Williams G, Tal I, Rodman D, et al. (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360: 1509\u20131517.","DOI":"10.1056\/NEJMoa0810780"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47 Noortman WA, Vriens D, de Geus-Oei LF, Slump CH, Aarntzen EH, et al. (2022) [(18)F]FDG-PET\/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas. Eur Radiol 32: 7227\u20137236.","DOI":"10.1007\/s00330-022-09034-5"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48 Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, et al. (2016) Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging 43: 1248\u20131257.","DOI":"10.1007\/s00259-015-3268-2"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49 Fagundes GFC, Almeida MQ (2022) Perioperative management of pheochromocytomas and sympathetic paragangliomas. J Endocr Soc 6: bvac004.","DOI":"10.1210\/jendso\/bvac004"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50 Zawadzka K, Wi\u0119ckowski K, Ma\u0142czak P, Wysocki M, Major P, et al. (2021) Selective <i>vs.<\/i> non-selective alpha-blockade prior to adrenalectomy for pheochromocytoma: systematic review and meta-analysis. Eur J Endocrinol 184: 751\u2013760.","DOI":"10.1530\/EJE-20-1301"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51 Buitenwerf E, Osinga TE, Timmers H, Lenders JWM, Feelders RA, et al. (2020) Efficacy of \u03b1-Blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial. J Clin Endocrinol Metab 105: 2381\u20132391.","DOI":"10.1210\/clinem\/dgz188"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52 Zhu CY, Hong JC, Kamdar NV, Hu MY, Tseng CH, et al. (2022) Comparison of preoperative alpha-blockade for resection of paraganglioma and pheochromocytoma. Endocr Pract 28: 889\u2013896.","DOI":"10.1016\/j.eprac.2022.06.013"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53 Jaiswal SK, Memon SS, Lila A, Sarathi V, Goroshi M, et al. (2021) Preoperative amlodipine is efficacious in preventing intraoperative HDI in pheochromocytoma: pilot RCT. J Clin Endocrinol Metab 106: e2907\u2013e2918.","DOI":"10.1210\/clinem\/dgab231"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54 Naruse M, Satoh F, Tanabe A, Okamoto T, Ichihara A, et al. (2018) Efficacy and safety of metyrosine in pheochromocytoma\/paraganglioma: a multi-center trial in Japan. Endocr J 65: 359\u2013371.","DOI":"10.1507\/endocrj.EJ17-0276"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55 Gruber LM, Jasim S, Ducharme-Smith A, Weingarten T, Young WF, et al. (2021) The role for metyrosine in the treatment of patients with pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 106: e2393\u2013e2401.","DOI":"10.1210\/clinem\/dgab130"},{"key":"55","doi-asserted-by":"crossref","unstructured":"56 Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, et al. (2018) Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg 268: 172\u2013178.","DOI":"10.1097\/SLA.0000000000002195"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57 Lafont M, Fagour C, Haissaguerre M, Darancette G, Wagner T, et al. (2015) Per-operative hemodynamic instability in normotensive patients with incidentally discovered pheochromocytomas. J Clin Endocrinol Metab 100: 417\u2013421.","DOI":"10.1210\/jc.2014-2998"},{"key":"57","doi-asserted-by":"crossref","unstructured":"58 Fu SQ, Wang SY, Chen Q, Liu YT, Li ZL, et al. (2020) Laparoscopic <i>versus<\/i> open surgery for pheochromocytoma: a meta-analysis. BMC Surg 20: 167.","DOI":"10.1186\/s12893-020-00824-6"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59 Li J, Wang Y, Chang X, Han Z (2020) Laparoscopic adrenalectomy (LA) <i>vs.<\/i> open adrenalectomy (OA) for pheochromocytoma (PHEO): a systematic review and meta-analysis. Eur J Surg Oncol 46: 991\u2013998.","DOI":"10.1016\/j.ejso.2020.02.009"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60 Schweitzer ML, Nguyen-Thi PL, Mirallie E, Vriens M, Raffaelli M, et al. (2019) Conversion during laparoscopic adrenalectomy for pheochromocytoma: a cohort study in 244 patients. J Surg Res 243: 309\u2013315.","DOI":"10.1016\/j.jss.2019.05.042"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61 Ma W, Mao Y, Zhuo R, Dai J, Fang C, et al. (2020) Surgical outcomes of a randomized controlled trial compared robotic <i>versus<\/i> laparoscopic adrenalectomy for pheochromocytoma. Eur J Surg Oncol 46: 1843\u20131847.","DOI":"10.1016\/j.ejso.2020.04.001"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62 Isiktas G, Nazli Avci S, Ergun O, Krishnamurthy V, Jin J, et al. (2022) Laparoscopic <i>versus<\/i> robotic adrenalectomy in pheochromocytoma patients. J Surg Oncol 126: 460\u2013464.","DOI":"10.1002\/jso.26918"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63 Fu SQ, Zhuang CS, Yang XR, Xie WJ, Gong BB, et al. (2020) Comparison of robot-assisted retroperitoneal laparoscopic adrenalectomy <i>versus<\/i> retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: a single-centre retrospective study. BMC Surg 20: 227.","DOI":"10.1186\/s12893-020-00895-5"},{"key":"63","unstructured":"64 Japanese Society of Endourology and Robotics (2020) Clinical guidelines for urological laparoscopic surgery. https:\/\/www.jsee.jp\/wordpress\/wp-content\/themes\/jsee\/assets\/pdf\/guideline_2020.pdf accessed on March 1, 2023 (In Japanese)."},{"key":"64","doi-asserted-by":"crossref","unstructured":"65 Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, et al. (2019) Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy <i>vs.<\/i> cortical-sparing adrenalectomy. JAMA Netw Open 2: e198898.","DOI":"10.1001\/jamanetworkopen.2019.8898"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66 Bhambhvani HP, Daneshvar MA, Peterson DJ, Ball MW (2021) Partial <i>versus<\/i> total adrenalectomy for pheochromocytoma: a population-based comparison of outcomes. Int Urol Nephrol 53: 2485\u20132492.","DOI":"10.1007\/s11255-021-03004-4"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67 Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, et al. (2013) High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol 168: 683\u2013687.","DOI":"10.1530\/EJE-12-1106"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68 Castinetti F, Taieb D, Henry JF, Walz M, Guerin C, et al. (2016) Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma. Eur J Endocrinol 174: R9\u2013R18.","DOI":"10.1530\/EJE-15-0549"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69 Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, et al. (2015) Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol 173: 757\u2013764.","DOI":"10.1530\/EJE-15-0483"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70 Ando Y, Ono Y, Sano A, Fujita N, Ono S, et al. (2022) Clinical characteristics and outcomes of pheochromocytoma crisis: a literature review of 200 cases. J Endocrinol Invest 45: 2313\u20132328.","DOI":"10.1007\/s40618-022-01868-6"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71 Whitelaw BC, Prague JK, Mustafa OG, Schulte KM, Hopkins PA, et al. (2014) Phaeochromocytoma [corrected] crisis. Clin Endocrinol (Oxf) 80: 13\u201322.","DOI":"10.1111\/cen.12324"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72 Prys-Roberts C, Farndon JR (2002) Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 26: 1037\u20131042.","DOI":"10.1007\/s00268-002-6667-z"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73 Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, et al. (2016) Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 18: 8\u201327.","DOI":"10.1002\/ejhf.424"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74 Sloand EM, Thompson BT (1984) Propranolol-induced pulmonary edema and shock in a patient with pheochromocytoma. Arch Intern Med 144: 173\u2013174.","DOI":"10.1001\/archinte.1984.00350130201036"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75 Sauneuf B, Chudeau N, Champigneulle B, Bouffard C, Antona M, et al. (2017) Pheochromocytoma crisis in the ICU: a french multicenter cohort study with emphasis on rescue extracorporeal membrane oxygenation. Crit Care Med 45: e657\u2013e665.","DOI":"10.1097\/CCM.0000000000002333"},{"key":"75","doi-asserted-by":"crossref","unstructured":"76 Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, et al. (2018) Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma <i>versus<\/i> urinary free or deconjugated O-methylated catecholamine metabolites. Clin Chem 64: 1646\u20131656.","DOI":"10.1373\/clinchem.2018.291369"},{"key":"76","doi-asserted-by":"crossref","unstructured":"77 Heavner MG, Krane LS, Winters SM, Mirzazadeh M (2015) Pheochromocytoma diagnosed pathologically with previous negative serum markers. J Surg Oncol 112: 492\u2013495.","DOI":"10.1002\/jso.24031"},{"key":"77","doi-asserted-by":"crossref","unstructured":"78 Hamidi O, Young WF, Jr., I\u00f1iguez-Ariza NM, Kittah NE, Gruber L, et al. (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 102: 3296\u20133305.","DOI":"10.1210\/jc.2017-00992"},{"key":"78","doi-asserted-by":"crossref","unstructured":"79 Feng F, Zhu Y, Wang X, Wu Y, Zhou W, et al. (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185: 1583\u20131590.","DOI":"10.1016\/j.juro.2010.12.050"},{"key":"79","unstructured":"80 Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, et al. (2003) Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas. Cancer Res 63: 5615\u20135621."},{"key":"80","doi-asserted-by":"crossref","unstructured":"81 Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812\u20138818.","DOI":"10.1200\/JCO.2005.03.1484"},{"key":"81","doi-asserted-by":"crossref","unstructured":"82 Timmers HJ, Pacak K, Huynh TT, Abu-Asab M, Tsokos M, et al. (2008) Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 93: 4826\u20134832.","DOI":"10.1210\/jc.2008-1093"},{"key":"82","doi-asserted-by":"crossref","unstructured":"83 Dreijerink KMA, Rijken JA, Compaijen CJ, Timmers H, van der Horst-Schrivers ANA, et al. (2019) Biochemically silent sympathetic paraganglioma, pheochromocytoma, or metastatic disease in SDHD mutation carriers. J Clin Endocrinol Metab 104: 5421\u20135426.","DOI":"10.1210\/jc.2019-00202"},{"key":"83","doi-asserted-by":"publisher","unstructured":"84 Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, et al. (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292: 943\u2013951.","DOI":"10.1001\/jama.292.8.943"},{"key":"84","doi-asserted-by":"crossref","unstructured":"85 Kimura N, Shiga K, Kaneko KI, Oki Y, Sugisawa C, et al. (2021) Immunohistochemical expression of choline acetyltransferase and catecholamine-synthesizing enzymes in head-and-neck and thoracoabdominal paragangliomas and pheochromocytomas. Endocr Pathol 32: 442\u2013451.","DOI":"10.1007\/s12022-021-09694-x"},{"key":"85","doi-asserted-by":"crossref","unstructured":"86 Lloyd S, Obholzer R, Tysome J (2020) British skull base society clinical consensus document on management of head and neck paragangliomas. Otolaryngol Head Neck Surg 163: 400\u2013409.","DOI":"10.1177\/0194599820915490"},{"key":"86","doi-asserted-by":"crossref","unstructured":"87 Williams MD (2017) Paragangliomas of the head and neck: an overview from diagnosis to genetics. Head Neck Pathol 11: 278\u2013287.","DOI":"10.1007\/s12105-017-0803-4"},{"key":"87","unstructured":"88 Kimura N, Asa SL, Gill AJ, Tischler AS (2024) Head and neck paraganglioma. In: WHO head and neck tumours (5th) Part B. World Health Organization, Lyon, France: 655\u2013658."},{"key":"88","doi-asserted-by":"crossref","unstructured":"89 Smith JD, Ellsperman SE, Basura GJ, Else T (2021) Re-evaluating the prevalence and factors characteristic of catecholamine secreting head and neck paragangliomas. Endocrinol Diabetes Metab 4: e00256.","DOI":"10.1002\/edm2.256"},{"key":"89","doi-asserted-by":"crossref","unstructured":"90 Cleere EF, Martin-Grace J, Gendre A, Sherlock M, O\u2019Neill JP (2022) Contemporary management of paragangliomas of the head and neck. Laryngoscope Investig Otolaryngol 7: 93\u2013107.","DOI":"10.1002\/lio2.706"},{"key":"90","doi-asserted-by":"crossref","unstructured":"91 Sandow L, Thawani R, Kim MS, Heinrich MC (2023) Paraganglioma of the head and neck: a review. Endocr Pract 29: 141\u2013147.","DOI":"10.1016\/j.eprac.2022.10.002"},{"key":"91","doi-asserted-by":"crossref","unstructured":"92 Yonamine M, Wasano K, Aita Y, Sugasawa T, Takahashi K, et al. (2021) Prevalence of germline variants in a large cohort of japanese patients with pheochromocytoma and\/or paraganglioma. <i>Cancers (Basel)<\/i> 13.","DOI":"10.3390\/cancers13164014"},{"key":"92","doi-asserted-by":"crossref","unstructured":"93 Moskovic DJ, Smolarz JR, Stanley D, Jimenez C, Williams MD, et al. (2010) Malignant head and neck paragangliomas: is there an optimal treatment strategy? Head Neck Oncol 2: 23.","DOI":"10.1186\/1758-3284-2-23"},{"key":"93","doi-asserted-by":"crossref","unstructured":"94 Malla SR, Bhalla AS, Manchanda S, Kandasamy D, Kumar R, et al. (2021) Dynamic contrast-enhanced magnetic resonance imaging for differentiating head and neck paraganglioma and schwannoma. Head Neck 43: 2611\u20132622.","DOI":"10.1002\/hed.26732"},{"key":"94","doi-asserted-by":"crossref","unstructured":"95 Satturwar SP, Rossi ED, Maleki Z, Cantley RL, Faquin WC, et al. (2021) Thyroid paraganglioma: a diagnostic pitfall in thyroid FNA. Cancer Cytopathol 129: 439\u2013449.","DOI":"10.1002\/cncy.22390"},{"key":"95","doi-asserted-by":"crossref","unstructured":"96 Fatima N, Pollom E, Soltys S, Chang SD, Meola A (2021) Stereotactic radiosurgery for head and neck paragangliomas: a systematic review and meta-analysis. Neurosurg Rev 44: 741\u2013752.","DOI":"10.1007\/s10143-020-01292-5"},{"key":"96","doi-asserted-by":"crossref","unstructured":"97 Hamidi O, Young WF Jr, Gruber L, Smestad J, Yan Q, et al. (2017) Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 87: 440\u2013450.","DOI":"10.1111\/cen.13434"},{"key":"97","doi-asserted-by":"crossref","unstructured":"98 Harrington JL, Farley DR, van Heerden JA, Ramin KD (1999) Adrenal tumors and pregnancy. World J Surg 23: 182\u2013186.","DOI":"10.1007\/PL00013159"},{"key":"98","doi-asserted-by":"crossref","unstructured":"99 Biggar MA, Lennard TW (2013) Systematic review of phaeochromocytoma in pregnancy. Br J Surg 100: 182\u2013190.","DOI":"10.1002\/bjs.8976"},{"key":"99","doi-asserted-by":"crossref","unstructured":"100 Bancos I, Atkinson E, Eng C, Young WF, Jr., Neumann HPH (2021) Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes Endocrinol 9: 13\u201321.","DOI":"10.1016\/S2213-8587(20)30363-6"},{"key":"100","doi-asserted-by":"publisher","unstructured":"101 Oliva R, Angelos P, Kaplan E, Bakris G (2010) Pheochromocytoma in pregnancy: a case series and review. Hypertension 55: 600\u2013606.","DOI":"10.1161\/HYPERTENSIONAHA.109.147579"},{"key":"101","doi-asserted-by":"crossref","unstructured":"102 Zuspan FP (1970) Urinary excretion of epinephrine and norepinephrine during pregnancy. J Clin Endocrinol Metab 30: 357\u2013360.","DOI":"10.1210\/jcem-30-3-357"},{"key":"102","doi-asserted-by":"crossref","unstructured":"103 Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G (2019) Pheochromocytoma and pregnancy. Endocrinol Metab Clin North Am 48: 605\u2013617.","DOI":"10.1016\/j.ecl.2019.05.006"},{"key":"103","unstructured":"104 Young WF Jr (2007) Endocrine hypertension. In: Melmed S, Polonsky KS, Larsen PR (eds.) Williams Textbook of Endocrinology (11th). Elsevier, Philadelphia, USA: 522\u2013530."},{"key":"104","unstructured":"105 Japan Society of Obstetrics and Gynecology, Japan Association of Obstetricians and Gynecologists (2020) Guidelines for obstetric practice in Japan 2020 (In Japanese)."},{"key":"105","doi-asserted-by":"crossref","unstructured":"106 Gruber LM, Young WF Jr, Bancos I (2021) Pheochromocytoma and paraganglioma in pregnancy: a new era. Curr Cardiol Rep 23: 60.","DOI":"10.1007\/s11886-021-01485-4"},{"key":"106","unstructured":"107 Japan Society for the Study of Hypertension in Pregnancy (2021) Guidelines for pregnancy-induced hypertension disorders 2021 (In Japanese)."},{"key":"107","doi-asserted-by":"crossref","unstructured":"108 Kuo MJM, Nazari MA, Jha A, Pacak K (2022) Pediatric metastatic pheochromocytoma and paraganglioma: clinical presentation and diagnosis, genetics, and therapeutic approaches. Front Endocrinol (Lausanne) 13: 936178.","DOI":"10.3389\/fendo.2022.936178"},{"key":"108","doi-asserted-by":"crossref","unstructured":"109 Jha A, Ling A, Millo C, Gupta G, Viana B, et al. (2018) Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45: 787\u2013797.","DOI":"10.1007\/s00259-017-3896-9"},{"key":"109","doi-asserted-by":"crossref","unstructured":"110 Jaiswal SK, Sarathi V, Malhotra G, Hira P, Shah R, et al. (2021) The utility of (68)Ga-DOTATATE PET\/CT in localizing primary\/metastatic pheochromocytoma and paraganglioma in children and adolescents\u2014a single-center experience. J Pediatr Endocrinol Metab 34: 109\u2013119.","DOI":"10.1515\/jpem-2020-0354"},{"key":"110","doi-asserted-by":"crossref","unstructured":"111 Virgone C, Andreetta M, Avanzini S, Chiaravalli S, De Pasquale D, et al. (2020) Pheochromocytomas and paragangliomas in children: Data from the Italian Cooperative Study (TREP). Pediatr Blood Cancer 67: e28332.","DOI":"10.1002\/pbc.28332"},{"key":"111","doi-asserted-by":"crossref","unstructured":"112 Yen K, Lodish M (2021) Pheochromocytomas and paragangliomas. Curr Opin Pediatr 33: 430\u2013435.","DOI":"10.1097\/MOP.0000000000001029"},{"key":"112","doi-asserted-by":"crossref","unstructured":"113 Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, et al. (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33: 90\u2013114.","DOI":"10.1007\/s12022-022-09704-6"},{"key":"113","doi-asserted-by":"crossref","unstructured":"114 van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, et al. (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10: 764\u2013771.","DOI":"10.1016\/S1470-2045(09)70164-0"},{"key":"114","doi-asserted-by":"crossref","unstructured":"115 Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, et al. (2014) Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 21: L13\u2013L16.","DOI":"10.1530\/ERC-13-0530"},{"key":"115","doi-asserted-by":"crossref","unstructured":"116 Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, et al. (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96: E1472\u2013E1476.","DOI":"10.1210\/jc.2011-1043"},{"key":"116","doi-asserted-by":"crossref","unstructured":"117 Burnichon N, Bri\u00e8re JJ, Lib\u00e9 R, Vescovo L, Rivi\u00e8re J, et al. (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19: 3011\u20133020.","DOI":"10.1093\/hmg\/ddq206"},{"key":"117","doi-asserted-by":"crossref","unstructured":"118 Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, et al. (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31: 181\u2013193.","DOI":"10.1016\/j.ccell.2017.01.001"},{"key":"118","doi-asserted-by":"crossref","unstructured":"119 Jiang J, Zhang J, Pang Y, Bechmann N, Li M, et al. (2020) Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 105.","DOI":"10.1210\/clinem\/dgaa502"},{"key":"119","doi-asserted-by":"crossref","unstructured":"120 N\u00f6lting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, et al. (2022) Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 43: 199\u2013239.","DOI":"10.1210\/endrev\/bnab019"},{"key":"120","doi-asserted-by":"crossref","unstructured":"121 Andrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, et al. (2018) Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. J Med Genet 55: 384\u2013394.","DOI":"10.1136\/jmedgenet-2017-105127"},{"key":"121","doi-asserted-by":"crossref","unstructured":"122 Benn DE, Zhu Y, Andrews KA, Wilding M, Duncan EL, et al. (2018) Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet 55: 729\u2013734.","DOI":"10.1136\/jmedgenet-2018-105427"},{"key":"122","doi-asserted-by":"crossref","unstructured":"123 Li SR, Nicholson KJ, McCoy KL, Carty SE, Yip L (2020) Clinical and biochemical features of pheochromocytoma characteristic of Von Hippel-Lindau syndrome. World J Surg 44: 570\u2013577.","DOI":"10.1007\/s00268-019-05299-y"},{"key":"123","unstructured":"124 Japan Endocrine Society (2014) Handbook for diagnosis and treatment of multiple endocrine neoplasia syndrome (In Japanese)."},{"key":"124","doi-asserted-by":"crossref","unstructured":"125 Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, et al. (2019) Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med 285: 187\u2013204.","DOI":"10.1111\/joim.12869"},{"key":"125","doi-asserted-by":"crossref","unstructured":"126 Horton C, LaDuca H, Deckman A, Durda K, Jackson M, et al. (2022) Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield. J Clin Endocrinol Metab 107: e1917\u2013e1923.","DOI":"10.1210\/clinem\/dgac014"},{"key":"126","doi-asserted-by":"crossref","unstructured":"127 Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, et al. (2017) Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol 13: 233\u2013247.","DOI":"10.1038\/nrendo.2016.185"},{"key":"127","doi-asserted-by":"crossref","unstructured":"128 Oudijk L, Gaal J, de Krijger RR (2019) The role of immunohistochemistry and molecular analysis of succinate dehydrogenase in the diagnosis of endocrine and non-endocrine tumors and related syndromes. Endocr Pathol 30: 64\u201373.","DOI":"10.1007\/s12022-018-9555-2"},{"key":"128","doi-asserted-by":"crossref","unstructured":"129 Buffet A, Ben Aim L, Leboulleux S, Drui D, Vezzosi D, et al. (2019) Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma. J Clin Endocrinol Metab 104: 1109\u20131118.","DOI":"10.1210\/jc.2018-02411"},{"key":"129","doi-asserted-by":"crossref","unstructured":"130 Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, et al. (2021) International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 17: 435\u2013444.","DOI":"10.1038\/s41574-021-00492-3"},{"key":"130","doi-asserted-by":"crossref","unstructured":"131 Davidoff DF, Benn DE, Field M, Crook A, Robinson BG, et al. (2022) Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study. J Clin Endocrinol Metab 107: e1907\u2013e1916.","DOI":"10.1210\/clinem\/dgac019"},{"key":"131","doi-asserted-by":"crossref","unstructured":"132 Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, et al. (2020) Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 38: 1443\u20131456.","DOI":"10.1097\/HJH.0000000000002438"},{"key":"132","doi-asserted-by":"crossref","unstructured":"133 Asban A, Kluijfhout WP, Drake FT, Beninato T, Wang E, et al. (2018) Trends of genetic screening in patients with pheochromocytoma and paraganglioma: 15-year experience in a high-volume tertiary referral center. J Surg Oncol 117: 1217\u20131222.","DOI":"10.1002\/jso.24961"},{"key":"133","doi-asserted-by":"crossref","unstructured":"134 Nockel P, El Lakis M, Gaitanidis A, Yang L, Merkel R, et al. (2018) Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery 163: 191\u2013196.","DOI":"10.1016\/j.surg.2017.05.025"},{"key":"134","doi-asserted-by":"crossref","unstructured":"135 Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, Guillet BA, Avram A, et al. (2019) European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46: 2112\u20132137.","DOI":"10.1007\/s00259-019-04398-1"},{"key":"135","doi-asserted-by":"crossref","unstructured":"136 Kolasinska-\u0106wik\u0142a A, P\u0119czkowska M, \u0106wik\u0142a JB, Micha\u0142owska I, Pa\u0142ucki JM, et al. (2019) A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. <i>J Clin Med<\/i> 8.","DOI":"10.3390\/jcm8070952"},{"key":"136","doi-asserted-by":"crossref","unstructured":"137 Perez K, Jacene H, Hornick JL, Ma C, Vaz N, et al. (2022) SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer 29: 533\u2013544.","DOI":"10.1530\/ERC-21-0392"},{"key":"137","doi-asserted-by":"crossref","unstructured":"138 O\u2019Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, et al. (2019) A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120: 1113\u20131119.","DOI":"10.1038\/s41416-019-0474-x"},{"key":"138","doi-asserted-by":"crossref","unstructured":"139 Ta\u00efeb D, Wanna GB, Ahmad M, Lussey-Lepoutre C, Perrier ND, et al. (2023) Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol 11: 345\u2013361.","DOI":"10.1016\/S2213-8587(23)00038-4"},{"key":"139","doi-asserted-by":"crossref","unstructured":"140 Richter S, Qiu B, Ghering M, Kunath C, Constantinescu G, et al. (2022) Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer 29: 213\u2013224.","DOI":"10.1530\/ERC-21-0359"},{"key":"140","doi-asserted-by":"crossref","unstructured":"141 Ta\u00efeb D, N\u00f6lting S, Perrier ND, Fassnacht M, Carrasquillo JA, et al. (2024) Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol 20: 168\u2013184.","DOI":"10.1038\/s41574-023-00926-0"},{"key":"141","unstructured":"142 Japan Endocrine Society (2013) Guidelines for the diagnosis of multiple endocrine neoplasia syndrome: actual condition and guidelines for diagnosis and treatment. https:\/\/www.j-endo.jp\/uploads\/files\/edu\/MEN.pdf accessed on June 26, 2023 (In Japanese)."},{"key":"142","unstructured":"143 Research group for standardization and actual condition survey of hereditary diseases causing various endocrine abnormalities (2017) Guidelines for the diagnosis and treatment of von Hippel-Lindau disease (VHL) 2017. https:\/\/www.kochi-u.ac.jp\/kms\/hs_urol\/pdf\/vhl_2017ver.pdf accessed on May 19, 2023 (In Japanese)."},{"key":"143","unstructured":"144 Neurofibromatosis Type 1 Clinical Guidelines Revision Committee, Japanese Dermatological Association (2018) Guidelines for the diagnosis and treatment of neurofibromatosis type 1 (Recklinghausen disease). https:\/\/www.dermatol.or.jp\/uploads\/uploads\/files\/NF1_GL.pdf accessed on June 26, 2023 (In Japanese)."},{"key":"144","doi-asserted-by":"crossref","unstructured":"145 Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, et al. (2012) Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 44: 385\u2013389.","DOI":"10.1055\/s-0031-1301339"},{"key":"145","doi-asserted-by":"crossref","unstructured":"146 Parasiliti-Caprino M, Lucatello B, Lopez C, Burrello J, Maletta F, et al. (2020) Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertens Res 43: 500\u2013510.","DOI":"10.1038\/s41440-019-0339-y"},{"key":"146","doi-asserted-by":"crossref","unstructured":"147 Li M, Prodanov T, Meuter L, Kerstens MN, Bechmann N, et al. (2023) Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 108: 397\u2013404.","DOI":"10.1210\/clinem\/dgac563"},{"key":"147","doi-asserted-by":"crossref","unstructured":"148 Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, et al. (2019) COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch 474: 721\u2013734.","DOI":"10.1007\/s00428-019-02553-5"},{"key":"148","doi-asserted-by":"crossref","unstructured":"149 Dhir M, Li W, Hogg ME, Bartlett DL, Carty SE, et al. (2017) Clinical predictors of malignancy in patients with pheochromocytoma and paraganglioma. Ann Surg Oncol 24: 3624\u20133630.","DOI":"10.1245\/s10434-017-6074-1"},{"key":"149","doi-asserted-by":"crossref","unstructured":"150 Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, et al. (2020) Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab 105: e4661\u20134670.","DOI":"10.1210\/clinem\/dgaa608"},{"key":"150","doi-asserted-by":"crossref","unstructured":"151 Pamporaki C, Prodanov T, Meuter L, Berends AMA, Bechmann N, et al. (2022) Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. Eur J Cancer 169: 32\u201341.","DOI":"10.1016\/j.ejca.2022.03.032"},{"key":"151","doi-asserted-by":"crossref","unstructured":"152 Holscher I, van den Berg TJ, Dreijerink KMA, Engelsman AF, Nieveen van Dijkum EJM (2021) Recurrence rate of sporadic pheochromocytomas after curative adrenalectomy: a systematic review and meta-analysis. J Clin Endocrinol Metab 106: 588\u2013597.","DOI":"10.1210\/clinem\/dgaa794"},{"key":"152","doi-asserted-by":"crossref","unstructured":"153 Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, et al. (2019) Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study. J Clin Endocrinol Metab 104: 2367\u20132374.","DOI":"10.1210\/jc.2018-01968"},{"key":"153","doi-asserted-by":"crossref","unstructured":"154 Kan Y, Zhang S, Wang W, Liu J, Yang J, et al. (2018) (68)Ga-somatostatin receptor analogs and (18)F-FDG PET\/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol 59: 1466\u20131474.","DOI":"10.1177\/0284185118764206"},{"key":"154","doi-asserted-by":"crossref","unstructured":"155 Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, et al. (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin 67: 93\u201399.","DOI":"10.3322\/caac.21388"},{"key":"155","doi-asserted-by":"crossref","unstructured":"156 Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, et al. (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405\u2013414.","DOI":"10.1530\/ERC-13-0494"},{"key":"156","doi-asserted-by":"crossref","unstructured":"157 Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, et al. (2009) Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score. Am J Surg Pathol 33: 599\u2013608.","DOI":"10.1097\/PAS.0b013e318190d12e"},{"key":"157","doi-asserted-by":"crossref","unstructured":"158 Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, et al. (2019) Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocr Relat Cancer 26: 539\u2013550.","DOI":"10.1530\/ERC-19-0024"},{"key":"158","doi-asserted-by":"crossref","unstructured":"159 Lee H, Jeong S, Yu Y, Kang J, Sun H, et al. (2020) Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis. J Med Genet 57: 217\u2013225.","DOI":"10.1136\/jmedgenet-2019-106324"},{"key":"159","doi-asserted-by":"crossref","unstructured":"160 Castro-Vega LJ, Buffet A, De Cubas AA, Casc\u00f3n A, Menara M, et al. (2014) Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 23: 2440\u20132446.","DOI":"10.1093\/hmg\/ddt639"},{"key":"160","doi-asserted-by":"crossref","unstructured":"161 Calsina B, Castro-Vega LJ, Torres-P\u00e9rez R, Inglada-P\u00e9rez L, Curr\u00e1s-Freixes M, et al. (2019) Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p\/TSC2\/mTOR axis in metastatic pheochromocytoma\/paraganglioma. Theranostics 9: 4946\u20134958.","DOI":"10.7150\/thno.35458"},{"key":"161","doi-asserted-by":"crossref","unstructured":"162 Wallace PW, Conrad C, Br\u00fcckmann S, Pang Y, Caleiras E, et al. (2020) Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. J Pathol 251: 378\u2013387.","DOI":"10.1002\/path.5472"},{"key":"162","doi-asserted-by":"crossref","unstructured":"163 Srimuninnimit V, Wampler GL (1991) Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 28: 217\u2013219.","DOI":"10.1007\/BF00685513"},{"key":"163","doi-asserted-by":"crossref","unstructured":"164 Jirari A, Charpentier A, Popescu S, Boidin P, Eisenmann B (1999) A malignant primary cardiac pheochromocytoma. Ann Thorac Surg 68: 565\u2013566.","DOI":"10.1016\/S0003-4975(99)00572-X"},{"key":"164","doi-asserted-by":"crossref","unstructured":"165 Nakane M, Takahashi S, Sekine I, Fukui I, Koizumi M, et al. (2003) Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 14: 1449\u20131451.","DOI":"10.1093\/annonc\/mdg358"},{"key":"165","doi-asserted-by":"crossref","unstructured":"166 Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401\u2013406.","DOI":"10.1200\/JCO.2005.03.6046"},{"key":"166","doi-asserted-by":"crossref","unstructured":"167 Sisson JC, Shapiro B, Shulkin BL, Urba S, Zempel S, et al. (1999) Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 22: 364\u2013370.","DOI":"10.1097\/00000421-199908000-00008"},{"key":"167","doi-asserted-by":"crossref","unstructured":"168 Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, et al. (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267\u2013273.","DOI":"10.7326\/0003-4819-109-4-267"},{"key":"168","doi-asserted-by":"crossref","unstructured":"169 Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 81: 642\u2013651.","DOI":"10.1111\/cen.12542"},{"key":"169","doi-asserted-by":"publisher","unstructured":"170 Huang H, Abraham J, Hung E, Averbuch S, Merino M, et al. (2008) Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113: 2020\u20132028.","DOI":"10.1002\/cncr.23812"},{"key":"170","doi-asserted-by":"crossref","unstructured":"171 Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, et al. (2013) Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 4: 103\u2013110.","DOI":"10.1007\/s12672-013-0133-2"},{"key":"171","doi-asserted-by":"crossref","unstructured":"172 Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M (2017) Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Horm Cancer 8: 108\u2013118.","DOI":"10.1007\/s12672-017-0284-7"},{"key":"172","doi-asserted-by":"crossref","unstructured":"173 Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, et al. (2017) SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer 24: L51\u2013L55.","DOI":"10.1530\/ERC-17-0086"},{"key":"173","doi-asserted-by":"crossref","unstructured":"174 Edstr\u00f6m Elder E, Hjelm Skog AL, H\u00f6\u00f6g A, Hamberger B (2003) The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29: 278\u2013283.","DOI":"10.1053\/ejso.2002.1413"},{"key":"174","doi-asserted-by":"crossref","unstructured":"175 Noshiro T, Honma H, Shimizu K, Kusakari T, Watanabe T, et al. (1996) Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy. Endocr J 43: 279\u2013284.","DOI":"10.1507\/endocrj.43.279"},{"key":"175","doi-asserted-by":"crossref","unstructured":"176 Tada K, Okuda Y, Yamashita K (1998) Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res 49: 295\u2013297.","DOI":"10.1159\/000023190"},{"key":"176","doi-asserted-by":"crossref","unstructured":"177 Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, et al. (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94: 2850\u20132856.","DOI":"10.1210\/jc.2008-2697"},{"key":"177","doi-asserted-by":"crossref","unstructured":"178 van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP (2014) (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 80: 487\u2013501.","DOI":"10.1111\/cen.12341"},{"key":"178","doi-asserted-by":"crossref","unstructured":"179 Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, et al. (2019) A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci Rep 9: 7625.","DOI":"10.1038\/s41598-019-43880-6"},{"key":"179","doi-asserted-by":"crossref","unstructured":"180 Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, et al. (2022) An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med 36: 267\u2013278.","DOI":"10.1007\/s12149-021-01699-0"},{"key":"180","doi-asserted-by":"crossref","unstructured":"181 Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, et al. (2014) Effects and safety of <sup>131<\/sup>I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J 61: 1171\u20131180.","DOI":"10.1507\/endocrj.EJ14-0211"},{"key":"181","doi-asserted-by":"crossref","unstructured":"182 Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A (2010) Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol 33: 79\u201382.","DOI":"10.1097\/COC.0b013e31819e2c28"},{"key":"182","unstructured":"183 Ministry of Health, Labour and Welfare (2022) https:\/\/www.mhlw.go.jp\/content\/12404000\/000914217.pdf accessed on August 1, 2025 (In Japanese)."},{"key":"183","unstructured":"184 Japan Radiological Society (2021) http:\/\/jsnm.org\/wp_jsnm\/wp-content\/uploads\/2021\/08\/%E7%97%85%E5%AE%A4%E3%83%9E%E3%83%8B%E3%83%A5%E3%82%A2%E3%83%AB.pdf accessed on August 1, 2025 (In Japanese)."},{"key":"184","doi-asserted-by":"crossref","unstructured":"185 Han S, Suh CH, Woo S, Kim YJ, Lee JJ (2019) Performance of (68)Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med 60: 369\u2013376.","DOI":"10.2967\/jnumed.118.211706"},{"key":"185","doi-asserted-by":"crossref","unstructured":"186 Satapathy S, Mittal BR, Bhansali A (2019) \u2018Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis\u2019. Clin Endocrinol (Oxf) 91: 718\u2013727.","DOI":"10.1111\/cen.14106"},{"key":"186","doi-asserted-by":"crossref","unstructured":"187 Lassen-Ramshad Y, Ozyar E, Alanyali S, Poortmans P, van Houtte P, et al. (2019) Paraganglioma of the head and neck region, treated with radiation therapy, a rare cancer network study. Head Neck 41: 1770\u20131776.","DOI":"10.1002\/hed.25611"},{"key":"187","doi-asserted-by":"crossref","unstructured":"188 Palmisciano P, Sagoo NS, Haider AS, Ogasawara C, Ogasawara M, et al. (2022) Primary paraganglioma of the spine: a systematic review of clinical features and surgical management in cauda equina <i>versus<\/i> non-cauda equina lesions. World Neurosurg 161: 190\u2013197.e120.","DOI":"10.1016\/j.wneu.2022.01.110"},{"key":"188","doi-asserted-by":"crossref","unstructured":"189 Breen W, Bancos I, Young WF, Jr., Bible KC, Laack NN, et al. (2018) External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3: 25\u201329.","DOI":"10.1016\/j.adro.2017.11.002"},{"key":"189","unstructured":"190 Tanabe A, Naruse M, Kinuya S, Katabami T (2011) Clinical characteristics of malignant pheochromocytoma: analysis of 77 cases by the Ministry of Health, Labour and Welfare Research Group on Intractable Diseases. Program of 84th Annual Meeting of Japan Endocrine Society O3-6-13 (Abstract). <i>Folia Endocrinologica Japonica<\/i> 87: 288 (In Japanese)."},{"key":"190","doi-asserted-by":"crossref","unstructured":"191 Yoneda T, Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328: 679\u2013687.","DOI":"10.1016\/j.bbrc.2004.11.070"},{"key":"191","unstructured":"192 Japanese Society of Medical Oncology (ed) (2022) Guidelines for the management of bone metastasis (2nd). Nankodo, Tokyo, Japan (In Japanese)."},{"key":"192","doi-asserted-by":"crossref","unstructured":"193 Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, et al. (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98: 1492\u20131497.","DOI":"10.1210\/jc.2012-4231"},{"key":"193","unstructured":"194 Kishimoto H, Ogino H, Kitagawa Y, Nomura T, Arai S, et al. (2023) Pathology and management of medication-related osteonecrosis of the jaw. Osteonecrosis of the Jaw Committee Position Paper 2023 https:\/\/www.jsoms.or.jp\/medical\/pdf\/work\/guideline_202307.pdf accessed on August 1, 2025 (In Japanese)."},{"key":"#cr-split#-194.1","unstructured":"195 Hisahara K (2014) Adjuvant analgesics. In: Japanese Society for Palliative Medicine, Committee for Palliative Care Guidelines"},{"key":"#cr-split#-194.2","unstructured":"(ed) Guidelines for pharmacologic management of cancer pain 2014. Kanehara Shuppan, Tokyo, Japan: 78-83 (In Japanese)."},{"key":"195","doi-asserted-by":"crossref","unstructured":"196 Mullen JP, Cartwright RC, Tisherman SE, Misage JR, Shapiro AP (1985) Pathogenesis and pharmacologic management of pseudo-obstruction of the bowel in pheochromocytoma. Am J Med Sci 290: 155\u2013158.","DOI":"10.1097\/00000441-198510000-00004"},{"key":"196","doi-asserted-by":"crossref","unstructured":"197 Mason LD, Prentice WM, Whitelaw BC (2009) An unusual case of severe constipation due to metastatic pheochromocytoma. J Pain Symptom Manage 37: e5\u2013e7.","DOI":"10.1016\/j.jpainsymman.2008.12.002"},{"key":"197","doi-asserted-by":"crossref","unstructured":"198 Sweeney AT, Malabanan AO, Blake MA, de las Morenas A, Cachecho R, et al. (2000) Megacolon as the presenting feature in pheochromocytoma. J Clin Endocrinol Metab 85: 3968\u20133972.","DOI":"10.1210\/jcem.85.11.6947"},{"key":"198","doi-asserted-by":"crossref","unstructured":"199 Thosani S, Ayala-Ramirez M, Rom\u00e1n-Gonz\u00e1lez A, Zhou S, Thosani N, et al. (2015) Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. Eur J Endocrinol 173: 377\u2013387.","DOI":"10.1530\/EJE-15-0456"},{"key":"199","doi-asserted-by":"crossref","unstructured":"200 Yamaguchi S, Shibata H, Miyashita K, Kurihara I, Murai-Takeda A, et al. (2010) Gastrointestinal pseudo-obstruction after debulking surgery of malignant pheochromocytoma, improved by intravenous administration of alpha-adrenergic receptor blocker, phentolamine. Hypertens Res 33: 753\u2013754.","DOI":"10.1038\/hr.2010.75"},{"key":"200","doi-asserted-by":"crossref","unstructured":"201 Karri V, Khan SL, Wilson Y (2005) Bowel perforation as a presenting feature of pheochromocytoma: case report and literature review. Endocr Pract 11: 385\u2013388.","DOI":"10.4158\/EP.11.6.385"},{"key":"201","doi-asserted-by":"crossref","unstructured":"202 So KW, Tsui HL, Tsang KH (2021) Colonic pseudo-obstruction as a rare complication of pheochromocytoma. Eur J Case Rep Intern Med 8: 002421.","DOI":"10.12890\/2021_002421"},{"key":"202","unstructured":"203 Osinga TE, Kerstens MN, van der Klauw MM, Koornstra JJ, Wolffenbuttel BH, et al. (2013) Intestinal pseudo-obstruction as a complication of paragangliomas: case report and literature review. Neth J Med 71: 512\u2013517."},{"key":"203","doi-asserted-by":"crossref","unstructured":"204 Neumann HPH, Young WF, Jr., Eng C (2019) Pheochromocytoma and Paraganglioma. N Engl J Med 381: 552\u2013565.","DOI":"10.1056\/NEJMra1806651"},{"key":"204","doi-asserted-by":"crossref","unstructured":"205 Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, et al. (2017) High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging 44: 476\u2013489.","DOI":"10.1007\/s00259-016-3527-x"},{"key":"205","doi-asserted-by":"crossref","unstructured":"206 Corssmit EPM, Snel M, Kapiteijn E (2020) Malignant pheochromocytoma and paraganglioma: management options. Curr Opin Oncol 32: 20\u201326.","DOI":"10.1097\/CCO.0000000000000589"},{"key":"206","doi-asserted-by":"crossref","unstructured":"207 Favier J, Pacak K, Clifton-Bligh R (2024) Advancements and challenges in pheochromocytoma and paraganglioma research: a collection of insights. <i>Endocr Relat Cancer<\/i> 31.","DOI":"10.1530\/ERC-24-0050"},{"key":"207","doi-asserted-by":"crossref","unstructured":"208 Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, et al. (2024) Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 403: 1061\u20131070.","DOI":"10.1016\/S0140-6736(23)02554-0"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/1\/73_EJ25-0165\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:42:19Z","timestamp":1768016539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/1\/73_EJ25-0165\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":208,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0165","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0165"}}